LRMR — Larimar Therapeutics Inc · catalysts, narrative & risks

Company Snapshot

Larimar Therapeutics (NASDAQ: LRMR) is a clinical-stage biotechnology company focused on rare diseases using its cell-penetrating peptide (intracellular delivery) platform. Its lead candidate, nomlabofusp (formerly CTI-1601), is being evaluated in a Phase 2 program as a potential treatment for Friedreich's ataxia (FA), a rare, progressive genetic disease [12][16][19]. As of late October 2026, the stock trades near the low end of its 52-week range ($1.92–$6.42), at roughly $2.5–2.7, with a market capitalization of ~$257M and negative trailing EPS of -$1.99 [19].

Recent Catalysts (July–October 2026)